Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 224

The DOI matches its Crossref record.

Topical Use of Human Recombinant Epidermal Growth Factor (h‐EGF) in Venous Ulcers

FALANGA, VINCENT, EAGLSTEIN, WILLIAM H., BUCALO, BRIAN, KATZ, MATTHEW H., HARRIS, BRIAN, CARSON, POLLY·1992·The Journal of Dermatologic Surgery and Oncology

Abstract

A great deal of interest has been focused recently on the potential use of synthetic polypeptide growth factors to stimulate healing of chronic wounds. In this pilot double‐blind randomized study conducted at a single center, we used human recombinant epidermal growth factor (h‐EGF) to treat 44 patients with venous ulceration of the lower extremities. An aqueous solution (10 μg/mh) of h‐EGF was applied topically to the ulcers twice a day until healing occurred or for a maximum of 10 weeks. Patients were evaluated weekly for measurements of ulcer size and for the formation of granulation tissue suitable for grafting. Nine patients were excluded from efficacy evaluation because of protocol violations. Therefore, 35 patients (17 h‐EGF, 18 placebo) were evaluable for efficacy, and 44 patients (22 h‐EGF, 22 placebo) were available for safety. The median baseline ulcer size for all patients was 18.5 cm2, and was not significantly different between h‐EGF and placebo group (12.9 cm2 versus 19.2 cm2, respectively, P= .27). By study end, six (35%) of h‐EGF treated patients and two (11%) in the placebo group had healed completely (P = .10). Another 6 patients (2 of 17 h‐EGF, 4 of 18 placebo; P= .50) developed healthy granulation tissue that was suitable for grafting. The median ulcer size reduction was 7% for h‐EGF versus 3% for placebo per week (P = .29), and 73% versus 33% at study end (P= .32). No untoward side effects were related to the application of h‐EGF. We conclude that topical application of h‐EGF, in the dose and manner used in this study, was safe but failed to significantly enhance reepithelialization of venous ulcers. However, a greater reduction in ulcer size and a larger number of healed ulcers with the use of h‐EGF are encouraging results.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1524-4725.1992.tb03514.x

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 224

Metadata

Authors
FALANGA, V., EAGLSTEIN, W. H., BUCALO, B., KATZ, M. H., HARRIS, B., & CARSON, P.
Venue
The Journal of Dermatologic Surgery and Oncology
Publisher
Wiley
Published
1992-07
Volume
18
Issue
7
Pages
604-606
ISSN
0148-0812 (ISSN-L)
OpenAlex
W1969690763
Cited by
224
References
0
FWCI
12.87
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Topical Use of Human Recombinant Epidermal Growth Factor (h‐EGF) in Venous Ulcers. https://app.cochat.ai/papers/10.1111/j.1524-4725.1992.tb03514.x
The paper
FALANGA, V., EAGLSTEIN, W. H., BUCALO, B., KATZ, M. H., HARRIS, B., & CARSON, P. (1992). Topical Use of Human Recombinant Epidermal Growth Factor (h‐EGF) in Venous Ulcers. The Journal of Dermatologic Surgery and Oncology. https://doi.org/10.1111/j.1524-4725.1992.tb03514.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.